0
Scientific EXPERT Act of 2025
3/17/2025, 3:58 PM
Summary of Bill HR 1532
The purpose of these meetings is to enhance the drug development process by bringing together a diverse group of stakeholders, including researchers, clinicians, patients, and industry representatives, to discuss and provide input on potential new drugs. By involving external experts in the decision-making process, the bill aims to improve the efficiency and effectiveness of drug development, ultimately leading to better and more innovative treatments for patients.
In addition to establishing a process for these externally led meetings, the bill also includes provisions for ensuring transparency and accountability in the drug development process. This includes requirements for public disclosure of meeting summaries and recommendations, as well as guidelines for managing conflicts of interest among meeting participants. Overall, Bill 119 HR 1532 seeks to promote collaboration and innovation in drug development by involving a broader range of stakeholders in the decision-making process. By fostering a more inclusive and transparent approach to drug development, the bill aims to improve the quality and availability of new treatments for patients.
Congressional Summary of HR 1532
Scientific External Process for Educated Review of Therapeutics Act of 2025 or the Scientific EXPERT Act of 2025
This bill requires the Food and Drug Administration (FDA) to facilitate and participate in externally led, science-focused drug development meetings to discuss the development of treatments for rare diseases and conditions.
The FDA must enter into an arrangement with the Reagan-Udall Foundation for the FDA under which the foundation agrees to convene such meetings. Meetings must be held at least four times a year, and each meeting must focus on a different rare disease or condition.
The foundation must establish a permanent steering committee to review and recommend topics for each meeting. In evaluating potential topics, the committee must consider unmet therapeutic needs, patient population sizes for different diseases and conditions, and whether a disease or condition would benefit from clarity and alignment on drug development questions, among other factors.
In planning each meeting, the foundation must develop a list of medical experts, drug sponsors, scientific organizations, patient organizations, and other entities to be invited to participate. Representatives of the FDA’s review divisions must attend each meeting.
After each meeting, the foundation must make available a summary of the meeting noting areas of consensus, areas where additional clarification or information is needed, and next steps agreed upon with the FDA.
The bill also requires the FDA to indicate whether it incorporated any input from these meetings when approving a new drug or biologic.
